Nuvelution Pharma Appoints Ways as Chief Medical Officer
26 October 2018 - - US-based Nuvelution Pharma, Inc has appointed Kirk Ways M.D., Ph.D. as chief medical officer effective immediately, the company said.

Dr. Ways is a seasoned industry expert with over 30 years of experience in medical research and will support the company's objective in advancing late-stage clinical assets toward FDA approval.

He will work alongside Barry Gertz, M.D., Ph.D., chief physician scientist of Nuvelution Pharma.

Ways has had extensive experience in pharmaceutical discovery and development.

Prior to joining Nuvelution, Dr. Ways served as Development Head of Cardiovascular and Metabolism at Janssen Pharmaceuticals, Inc. Prior to joining Janssen, Dr.

Ways served in leadership capacities at BioStratum Inc. as vice president and Chief Development officer, Aventis as Senior Global Medical Leader and Project Team Leader and Lilly Research Laboratories as a Research Fellow with responsibilities for the preclinical and clinical development for agents treating the chronic complications of diabetes.

Prior to joining the pharmaceutical industry, Dr. Ways served as director of the Diabetes Center, vice chairman for the Department of Internal Medicine, Endocrinology Section Head and Professor of Medicine at East Carolina School of Medicine.

An accomplished researcher, Dr. Ways has authored more than one hundred publications in the fields of diabetes and cancer.

Dr. Ways earned his M.D. with honors and a Ph.D. in Pharmacology from the University of North Carolina and graduated with a B.A. Magna Cum Laude from Bridgewater College.